News & Events about Erasca Inc.
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision ...
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Alexander W. Casdin purchased 20,000 shares of the companys stock in a transaction dated Monday, April 10th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $55,200.00. Following the acquisition, ...
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Alexander W. Casdin bought 20,000 shares of Erasca stock in a transaction dated Monday, April 10th. The stock was purchased at an average price of $2.76 per share, with a total value of $55,200.00. Following the purchase, the director now owns 463,974 ...
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN DIEGO, April 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim ...